Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Dermavant Sciences, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05186805
- Locations
- 🇨🇦
Dermavant Investigative Site, Calgary, Alberta, Canada
Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Dermavant Sciences, Inc.
- Target Recruit Count
- 728
- Registration Number
- NCT05142774
- Locations
- 🇨🇦
Dermavant Investigative Site, Montréal, Quebec, Canada
🇺🇸Dermavant lnvestigative Site, Greenville, South Carolina, United States
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)
Phase 3
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: vehicle cream
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Dermavant Sciences, Inc.
- Target Recruit Count
- 406
- Registration Number
- NCT05032859
- Locations
- 🇨🇦
Dermavant Investigative Site, Windsor, Ontario, Canada
🇺🇸Dermanvant Investigative Site, Brooklyn, New York, United States
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults
Phase 3
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Vehicle cream
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Dermavant Sciences, Inc.
- Target Recruit Count
- 407
- Registration Number
- NCT05014568
- Locations
- 🇨🇦
Dermavant Investigative Site, Montréal, Quebec, Canada